SCHEMBL7170900

SCHEMBL7170900

CCOC(=O)c1cnc2c(CC)cc(C#N)cc2c1NCc1cc(OC)cc(OC)c1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 8/20 0.74
MAPT P10636 9/20 0.52
ALDH1A1 P00352 6/20 0.52
LMNA P02545 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
KDM4E B2RXH2 4/20 0.52
HPGD P15428 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
GAA P10253 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.44
POLB P06746 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KMT2A Q03164 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7168877 0.93 PDE5A (0.77) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7168296 0.91 PDE5A (0.65) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7167640 0.90 PDE5A (0.76) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7170874 0.89 PDE5A (0.74) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7160498 0.88 PDE5A (0.75) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7167673 0.88 PDE5A (0.73) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7170669 0.87 PDE5A (0.74) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7164927 0.86 PDE5A (0.73) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7167682 0.86 PDE5A (0.73) PDE5AMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL7163862 0.86 PDE5A (0.83) PDE5AMAPTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase BI YINGZHI (US) 2003-12-04 US claimed
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase BRISTOL-MYERS SQUIBB COMPANY 2002-11-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE3A, PDE2A PDE5A 1/4885MAPT 4486/4885ALDH1A1 301/4885
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE2A, PDE3A PDE5A 1/4885MAPT 4376/4885ALDH1A1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.